Report cover image

Autoinjectors Market

Publisher Fortune Business Insights Pvt. Ltd.
Published Oct 01, 2024
Length 150 Pages
SKU # FOB19224350

Description

Autoinjectors Market



Growth Factors of Autoinjectors Market

The autoinjectors market size was valued at USD 518.46 billion in 2023, and the market is now projected to grow from USD 542.21 billion in 2024 to USD 886.80 billion by 2032, exhibiting a CAGR of 6.3% during the forecast period of 2023-2030.

The COVID-19 pandemic posed significant challenges on the autoinjectors market growth. Due to lack of industrial operations and a halt in commercial campaigns, implementation of government policies, investments in projects and other initiatives due to covid pandemic., which lead a decline in the autoinjectors market expansion. Lockdown enacted in numerous nations have hindered the manufacturing and caused transportation delays. In addition, worldwide restrictions have caused a halt in economic activities. Despite the challenges of covid pandemic, the battery plate sector has proven to be robust. Although the construction of electric vehicle has been delayed due to shortage of man power and procurement concerns of raw material.

Technological developments in device platforms to present profitable will promote autoinjectors market growth prospects during projected period. The increasing prevalence of chronic illnesses like diabetes and rheumatoid arthritis is driving up demand for autoinjectors worldwide. In order to facilitate quicker development and lower device costs, a number of market participants are reorienting their attention toward the development of platform device technologies as a result of the high incidence. Furthermore, market expansion will be fueled by major players' increased focus on enabling high-volume delivery of a variety of biologics and biosimilars for patients in their homes.

Patients' widespread adoption of disposable autoinjectors to accelerate market growth during projected period. Injectable systems have been used by medical practitioners as practical medication delivery tools for administering subcutaneous injections to patients. However, patients' desire for conventional injectable devices was constrained by drawbacks such needle stick injuries, repeated low-dose injections, and high hospital visit expenses.

Comprehensive Analysis of Autoinjectors Market

The autoinjectors market and healthcare industry is rising at an exponential rate due to its market segmentation. This market expansion effectively provides a detailed regional assessment considering the dominant supply and demand forces that impact the pharmacy benefit management industry. These segmentations are methodically segregated by types, by route of application, by route of administration and by end users. The types segmentations include, Disposable, and Reusable, and by Application segmentations include Autoimmune Disorders, Diabetes, Emergency Care, and Others wile by Route of Administration segmentations include Intramuscular and Subcutaneous. However, the Distribution Channel segmentations include Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies.

The North America region lead the autoinjectors market by benefitting a market size of USD 65.81 billion in 2023 due to the major players' increased R&D and the development of new technology in self-injector devices to enable in-patient treatment, as well as the growing emphasis and recommendation of autoinjector prescriptions against anaphylactic episodes by healthcare professionals.

The top players in the market play a crucial role in the healthcare industry assuring industrial prospectus growth and setting market standards. These players include, Viatris Inc. (U.S.), Teva Pharmaceuticals, Inc. (Netherlands), Ypsomed AG (Switzerland), Recipharm AB (Sweden), Becton Dickinson and Company (U.S.), Halozyme, Inc. (U.S.), AstraZeneca (U.K.), Bristol-Myers Squibb (U.S.), Phillips-Medisize (U.S.), SHL Medical AG (Switzerland), Xeris Pharmaceuticals, Inc. (U.S.) these market players provide a level-playing competitive landscape.

In April 2022, Halozyme Therapeutics, Inc. entered a final agreement to buy Antares Pharma, Inc. A market leader in the autoinjector platform business for specialized goods and medication delivery was created through the purchase.

Segmentation Table

ATTRIBUTE DETAILS

Study Period 2019-2032

Base Year 2023

Estimated Year 2024

Forecast Period 2024-2032

Historical Period 2019-2022

Growth Rate CAGR of 12.3% over 2024 to 2032

Unit Value (USD billion)

Growth Rate CAGR of 12.3% from 2024-2032

Segmentation By Type
  • Disposable
  • Reusable
By Application
  • Autoimmune Disorders
  • Diabetes
  • Emergency Care
  • Others
By Route of Administration
  • Intramuscular
  • Subcutaneous
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
By Geography
  • North America (By Type, By Application, By Distribution Channel, and By Country)
  • U.S. (By Type)
  • Canada (By Type)
  • Europe (By Type, By Diabetes Type, By Distribution Channel, and By Country/Sub-region)
  • U.K. (By Type)
  • Germany (By Type)
  • France (By Type)
  • Italy (By Type)
  • Spain (By Type)
  • Rest of Europe (By Type)
  • Asia Pacific (By Type, By Application, By Distribution Channel, and By Country/Sub-region)
  • China (By Type)
  • Japan (By Type)
  • India (By Type)
  • Australia (By Type)
  • Southeast Asia (By Type)
  • Rest of Asia Pacific (By Type)
  • Latin America (By Type, By Application, By Distribution Channel, and By Country/Sub-region)
  • Brazil (By Type)
  • Mexico (By Type)
  • Rest of Latin America (By Type)
  • Middle East & Africa (By Type, By Application, By Distribution Channel, and By Country/Sub-region)
  • GCC (By Type)
  • South Africa (By Type)
  • Rest of Middle East & Africa (By Type)


Please Note: It will take 5-6 business days to complete the report upon order confirmation.

Table of Contents

150 Pages
1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Market Trends
4. Key Insights
4.1. Prevalence of Chronic Diseases, By Key Countries/Regions, 2023
4.2. New Product Launches, By Key Players
4.3. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
4.4. Impact of COVID-19 on the Market
5. Global Autoinjectors Market Analysis, Insights and Forecast, 2019-2032
5.1. Market Analysis, Insights and Forecast – By Type
5.1.1. Disposable
5.1.2. Reusable
5.2. Market Analysis, Insights and Forecast – By Application
5.2.1. Autoimmune Disorders
5.2.2. Diabetes
5.2.3. Emergency Care
5.2.4. Others
5.3. Market Analysis, Insights and Forecast – By Route of Administration
5.3.1. Intramuscular
5.3.2. Subcutaneous
5.4. Market Analysis, Insights and Forecast – By Distribution Channel
5.4.1. Hospital Pharmacies
5.4.2. Retail Pharmacies
5.4.3. Online Pharmacies
5.5. Market Analysis, Insights and Forecast – By Region
5.5.1. North America
5.5.2. Europe
5.5.3. Asia Pacific
5.5.4. Latin America
5.5.5. Middle East and Africa
6. North America Autoinjectors Market Analysis, Insights and Forecast, 2019-2032
6.1. Market Analysis, Insights and Forecast – By Type
6.1.1. Disposable
6.1.2. Reusable
6.2. Market Analysis, Insights and Forecast – By Application
6.2.1. Autoimmune Disorders
6.2.2. Diabetes
6.2.3. Emergency Care
6.2.4. Others
6.3. Market Analysis, Insights and Forecast – By Route of Administration
6.3.1. Intramuscular
6.3.2. Subcutaneous
6.4. Market Analysis, Insights and Forecast – By Distribution Channel
6.4.1. Hospital Pharmacies
6.4.2. Retail Pharmacies
6.4.3. Online Pharmacies
6.5. Market Analysis, Insights and Forecast – By Country
6.5.1. U.S.
6.5.2. Canada
7. Europe Autoinjectors Market Analysis, Insights and Forecast, 2019-2032
7.1. Market Analysis, Insights and Forecast – By Type
7.1.1. Disposable
7.1.2. Reusable
7.2. Market Analysis, Insights and Forecast – By Application
7.2.1. Autoimmune Disorders
7.2.2. Diabetes
7.2.3. Emergency Care
7.2.4. Others
7.3. Market Analysis, Insights and Forecast – By Route of Administration
7.3.1. Intramuscular
7.3.2. Subcutaneous
7.4. Market Analysis, Insights and Forecast – By Distribution Channel
7.4.1. Hospital Pharmacies
7.4.2. Retail Pharmacies
7.4.3. Online Pharmacies
7.5. Market Analysis, Insights and Forecast – By Country/Sub-region
7.5.1. Germany
7.5.2. U.K.
7.5.3. France
7.5.4. Italy
7.5.5. Spain
7.5.6. Rest of Europe
8. Asia Pacific Autoinjectors Market Analysis, Insights and Forecast, 2019-2032
8.1. Market Analysis, Insights and Forecast – By Type
8.1.1. Disposable
8.1.2. Reusable
8.2. Market Analysis, Insights and Forecast – By Application
8.2.1. Autoimmune Disorders
8.2.2. Diabetes
8.2.3. Emergency Care
8.2.4. Others
8.3. Market Analysis, Insights and Forecast – By Route of Administration
8.3.1. Intramuscular
8.3.2. Subcutaneous
8.4. Market Analysis, Insights and Forecast – By Distribution Channel
8.4.1. Hospital Pharmacies
8.4.2. Retail Pharmacies
8.4.3. Online Pharmacies
8.5. Market Analysis, Insights and Forecast – By Country/Sub-region
8.5.1. China
8.5.2. Japan
8.5.3. India
8.5.4. Australia
8.5.5. Southeast Asia
8.5.6. Rest of Asia Pacific
9. Latin America Autoinjectors Market Analysis, Insights and Forecast, 2019-2032
9.1. Market Analysis, Insights and Forecast – By Type
9.1.1. Disposable
9.1.2. Reusable
9.2. Market Analysis, Insights and Forecast – By Application
9.2.1. Autoimmune Disorders
9.2.2. Diabetes
9.2.3. Emergency Care
9.2.4. Others
9.3. Market Analysis, Insights and Forecast – By Route of Administration
9.3.1. Intramuscular
9.3.2. Subcutaneous
9.4. Market Analysis, Insights and Forecast – By Distribution Channel
9.4.1. Hospital Pharmacies
9.4.2. Retail Pharmacies
9.4.3. Online Pharmacies
9.5. Market Analysis, Insights and Forecast – By Country/Sub-region
9.5.1. Brazil
9.5.2. Mexico
9.5.3. Rest of Latin America
10. Middle East & Africa Autoinjectors Market Analysis, Insights and Forecast, 2019-2032
10.1. Market Analysis, Insights and Forecast – By Type
10.1.1. Disposable
10.1.2. Reusable
10.2. Market Analysis, Insights and Forecast – By Application
10.2.1. Autoimmune Disorders
10.2.2. Diabetes
10.2.3. Emergency Care
10.2.4. Others
10.3. Market Analysis, Insights and Forecast – By Route of Administration
10.3.1. Intramuscular
10.3.2. Subcutaneous
10.4. Market Analysis, Insights and Forecast – By Distribution Channel
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Market Analysis, Insights and Forecast – By Country/Sub-region
10.5.1. GCC
10.5.2. Saudi Arabia
10.5.3. Rest of Middle East & Africa
11. Competitive Analysis
11.1. Global Market Share Analysis (2023)
11.2. Company Profiles
11.2.1. Viatris Inc.
11.2.1.1. Overview
11.2.1.2. Products & Services
11.2.1.3. SWOT Analysis
11.2.1.4. Recent Developments
11.2.1.5. Strategies
11.2.1.6. Financials (Based on Availability)
11.2.2. Teva Pharmaceuticals, Inc.
11.2.2.1. Overview
11.2.2.2. Products & Services
11.2.2.3. SWOT Analysis
11.2.2.4. Recent Developments
11.2.2.5. Strategies
11.2.2.6. Financials (Based on Availability)
11.2.3. Ypsomed AG
11.2.3.1. Overview
11.2.3.2. Products & Services
11.2.3.3. SWOT Analysis
11.2.3.4. Recent Developments
11.2.3.5. Strategies
11.2.3.6. Financials (Based on Availability)
11.2.4. Recipharm AB
11.2.4.1. Overview
11.2.4.2. Products & Services
11.2.4.3. SWOT Analysis
11.2.4.4. Recent Developments
11.2.4.5. Strategies
11.2.4.6. Financials (Based on Availability)
11.2.5. Becton Dickinson and Company
11.2.5.1. Overview
11.2.5.2. Products & Services
11.2.5.3. SWOT Analysis
11.2.5.4. Recent Developments
11.2.5.5. Strategies
11.2.5.6. Financials (Based on Availability)
11.2.6. Halozyme, Inc.
11.2.6.1. Overview
11.2.6.2. Products & Services
11.2.6.3. SWOT Analysis
11.2.6.4. Recent Developments
11.2.6.5. Strategies
11.2.6.6. Financials (Based on Availability)
11.2.7. AstraZeneca
11.2.7.1. Overview
11.2.7.2. Products & Services
11.2.7.3. SWOT Analysis
11.2.7.4. Recent Developments
11.2.7.5. Strategies
11.2.7.6. Financials (Based on Availability)
11.2.8. Bristol-Myers Squibb
11.2.8.1. Overview
11.2.8.2. Products & Services
11.2.8.3. SWOT Analysis
11.2.8.4. Recent Developments
11.2.8.5. Strategies
11.2.8.6. Financials (Based on Availability)
11.2.9. Phillips-Medisize
11.2.9.1. Overview
11.2.9.2. Products & Services
11.2.9.3. SWOT Analysis
11.2.9.4. Recent Developments
11.2.9.5. Strategies
11.2.9.6. Financials (Based on Availability)
11.2.10. SHL Medical AG
11.2.10.1. Overview
11.2.10.2. Products & Services
11.2.10.3. SWOT Analysis
11.2.10.4. Recent Developments
11.2.10.5. Strategies
11.2.10.6. Financials (Based on Availability)
11.2.11. Xeris Pharmaceuticals, Inc.
11.2.11.1. Overview
11.2.11.2. Products & Services
11.2.11.3. SWOT Analysis
11.2.11.4. Recent Developments
11.2.11.5. Strategies
11.2.11.6. Financials (Based on Availability)

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us